Bio-Techne stock plunges 16.36% and underperforms rivals

7 articles · Updated · MarketWatch · May 6

Shares closed at $47.41 on Wednesday as the S&P 500 rose 1.46% and the Dow gained 1.24% in a broadly positive US market session.
The stock finished 34.31% below its 52-week high of $72.16 reached on 22 January, while trading volume jumped to 11.9 million shares from a 50-day average of 2.2 million.
Among peers, Amgen rose 0.46% and BioMarin gained 2.55%, while Charles River Laboratories fell 1.97%, leaving Bio-Techne the clear laggard in the group.

After a 16% stock plunge, Bio-Techne is betting on a major acquisition. Can this strategic pivot actually revive its fortunes?

Management blames 'timing issues' for a massive stock drop. What is the real story behind the company's sudden revenue shortfall?